Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. IBM
9. HOOD
10. ABBV

Go back to Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

Vir Biotechnology (VIR) Stock Soars on Early Omicron Testing Data

December 2, 2021 6:03 AM EST

Shares of Vir Biotechnology (NASDAQ: VIR) are up nearly 9% after the company said that preliminary data shows that its sotrovimab cocktail, developed together with GlaxoSmithKline plc (NYSE: GSK), retains activity against Omicron.

Two companies said that sotrovimab showed it can protect against all tested variants of concern. VIR and GSK are now... More